Preventing surgical-site infections in nasal carriers of Staphylococcus aureus

New England Journal of Medicine

Volumn 362, Issue 1, 2010, Pages 9-17

  Bode, Lonneke G M ^a   Kluytmans, Jan A J W ^b,c   Wertheim, Heiman F L ^a,g   Bogaers, Diana ^b   Vandenbroucke Grauls, Christina M J E ^c   Roosendaal, Robert ^c   Troelstra, Annet ^d   Box, Adrienne T A ^d   Voss, Andreas ^e,f   Van Der Tweel, Ingeborg ^d   Van Belkum, Alex ^a   Verbrugh, Henri A ^a   Vos, Margreet C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f SINT MAARTENSKLINIEK   (Netherlands)

^g OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE GLUCONATE; PLACEBO; PSEUDOMONIC ACID; SOAP; ANTIINFECTIVE AGENT; CHLORHEXIDINE;

ADULT; ARTICLE; BACTERIUM IDENTIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NOSE IRRITATION; NOSE SMEAR; OINTMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SKIN IRRITATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; CAUSE OF DEATH; CROSS INFECTION; GENETICS; HETEROZYGOTE; INTRANASAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; LENGTH OF STAY; MICROBIOLOGY; MIDDLE AGED; NOSE CAVITY; POLYMERASE CHAIN REACTION; SKIN; STATISTICAL MODEL;

ADMINISTRATION, INTRANASAL; ANTI-INFECTIVE AGENTS; CARRIER STATE; CAUSE OF DEATH; CHLORHEXIDINE; CROSS INFECTION; DOUBLE-BLIND METHOD; FEMALE; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIERS ESTIMATE; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MUPIROCIN; NASAL CAVITY; OINTMENTS; POLYMERASE CHAIN REACTION; SKIN; SOAPS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURGICAL WOUND INFECTION;

EID: 74049131276     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0808939     Document Type: Article

References (31)

1. Luzar MA, Coles GA, Faller B, et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 1990;322:505-9.
2. Kluytmans JA, Mouton JW, Ijzerman EP, et al. Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 1995;171:216-9.
3. Nouwen J, Schouten J, Schneebergen P, et al. Staphylococcus aureus carriage patterns and the risk of infections associated with continuous peritoneal dialysis. J Clin Microbiol 2006;44:2233-6.
4. Weinstein HJ. The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications. N Engl J Med 1959;260:1303-8.
5. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N Engl J Med 2001;344:11-6.
6. Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004;364:703-5.
7. Laupland KB, Conly JM. Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 2003;37:933-8.
8. Kluytmans JA, Manders MJ, van Bommel E, Verbrugh H. Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect Control Hosp Epidemiol 1996;17:793-7.
9. Boelaert JR, Van Landuyt HW, Godard CA, et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993;8:235-9.
10. Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc Nephrol 1996;7:2403-8.
11. Wertheim HF, Vos MC, Ott A, et al. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med 2004;140:419-25.
12. Kluytmans JA, Mouton JW, Vanden-Bergh MF, et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996;17:780-5.
13. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002;346:1871-7.
14. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. Clin Infect Dis 2002;35:353-8.
15. Paule SM, Pasquariello AC, Hacek DM, et al. Direct detection of Staphylococcus aureus from adult and neonate nasal swab specimens using real-time polymerase chain reaction. J Mol Diagn 2004;6:191-6.
16. Hacek DM, Robb WJ, Paule SM, Kudrna JC, Stamos VP, Peterson LR. Staphylococcus aureus nasal decolonization in joint replacement surgery reduces infection. Clin Orthop Relat Res 2008;466:1349-55.
17. Choudhurry RS, Melles DC, Eadie K, et al. Direct detection of human Staphylococcus aureus carriage in the nose using the Lightcycler Staphylococcus kit. J Microbiol Methods 2006;65:354-6.
18. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005;5:751-62.
19. Kaiser AB, Kernodle DS, Barg NL, Petracek MR. Influence of preoperative showers on staphylococcal skin colonization: a comparative trial of antiseptic skin cleansers. Ann Thorac Surg 1988;45:35-8.
20. Horan TC, Gaynes RP. Surveillance of nosocomial infections. In: Mayhall CG, ed. Hospital epidemiology and infection control. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2004:1659-702.
21. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-9.
22. Doern GV, Vautour R, Gaudet M, Levy B. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol 1994;32:1757-62.
23. van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J Antimicrob Chemother 2008;61:254-61.
24. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008;4:CD006216.
25. Solberg CO. A study of carriers of Staphylococcus aureus with special regard to quantitative bacterial estimations. Acta Med Scand Suppl 1965;436:1-96.
26. Williams RE. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev 1963;27:56-71.
27. Wendt C, Schinke S, Württemberger M, Oberdorfer K, Bock-Hensley O, von Baum H. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant Staphylococcus aureus: a randomized, placebo-controlled, double-blind clinical trial. Infect Control Hosp Epidemiol 2007;28:1036-43.
28. Deshpande LM, Fix AM, Pfaller MA, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis 2002;42:283-90.
29. Wertheim HF, Vos MC, Boelens HA, et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004;56:321-5.
30. Miller LG, Diep BA. Clinical practice: colonization, fomites, and virulence: rethinking the pathogenesis of community-associated methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008;46:752-60.
31. Mertz D, Frei R, Periat N, et al. Exclusive Staphylococcus aureus throat carriage: at-risk populations. Arch Intern Med 2009;169:172-8.